Adonix

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adonix

Quick Facts

Property Description
Active ingredient Sildenafil Citrate
Form Oral tablet (Film-coated)
Pharmacological class Phosphodiesterase type 5 (PDE5) inhibitor
Origin Synthetic compound

1. Adonix: Definition and Pharmacological Class

Adonix is a synthetic prescription medication whose core activity is driven by the single active ingredient, Sildenafil Citrate. Pharmacologically, it is classified as a highly selective Phosphodiesterase type 5 (PDE5) inhibitor.

This classification places Adonix within a group of drugs designed to modulate enzyme activity within certain vascular smooth muscle tissues. The Sildenafil compound is a synthetic organic molecule and is utilized as a monotherapy product, meaning its sole therapeutic effect is derived from this chemical substance. The prescription-only status of this medication differentiates it from over-the-counter preparations.

2. Composition and Pharmaceutical Form

Adonix is manufactured and presented primarily as an oral tablet, commonly taking a film-coated form, which is intended for reliable oral administration. The drug's mechanism involves blocking the PDE5 enzyme, which leads to vasodilation.

The active substance, Sildenafil Citrate, is combined with pharmaceutical excipients, which form the excipient-based solid oral vehicle of the tablet. This physical form is the established standard for delivering the drug consistently, ensuring the active chemical component is protected and efficiently released into the gastrointestinal system following ingestion.

3. General Principle and Therapeutic Utility

The general principle of Adonix's action is targeted enzyme inhibition, specifically blocking the PDE5 enzyme, which ultimately prevents the rapid breakdown of a crucial signaling molecule necessary for smooth muscle function. The drug provides a sustained action of PDE5 inhibition.

By promoting the accumulation of this molecule, the drug supports smooth muscle relaxation and facilitates vasodilatation (blood vessel widening). This mechanism helps to sustain and enhance localized blood flow in response to a biological stimulus, fulfilling the drug's general purpose of improving vascular dynamics where such flow is physiologically or medically essential.

What side effects are possible with Adonix?

Possible Side Effects and Safety Information

The safety profile of Adonix (Sildenafil Citrate) is documented according to regulatory standards, classifying potential effects by frequency and the organ system affected. This classification is based on data from clinical studies and post-marketing surveillance, providing a structured understanding of the medicine's risk characteristics.


Frequency-Classified Adverse Reactions

The most frequently reported effects include those classified as Very Common (ge 1 in 10 patients), such as Headache and Flushing (vasodilation). Effects classified as Common (ge 1 in 100 to <1 in 10 patients) include Dizziness, Dyspepsia, Nasal Congestion, and Visual Disturbances (e.g., blurred vision or color tinge).

Serious Adverse Reactions and Safety Constraints

Certain rare but clinically significant reactions are documented. These include the occurrence of Priapism (a prolonged erection lasting greater than four hours), Sudden Decrease or Loss of Hearing, and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), a cause of vision loss.

Regulatory documentation establishes explicit restrictions on the use of Adonix. The medication is contraindicated for use with any form of organic nitrates or nitric oxide donors due to the high risk of severe, life-threatening hypotension. Concomitant use with guanylate cyclase stimulators is also restricted.

Population-Specific Considerations

Safety statements address specific patient groups, noting reduced systemic clearance in individuals with Severe Hepatic Impairment and Severe Renal Impairment. In older adults, clearance may also be reduced. The risk of symptomatic hypotension when used with alpha-blockers is noted, with the highest risk period being within the first four hours after dosing.

Overdose and Emergency Response

Overdose and when to seek help

Officially documented overdose presentations of Adonix (Sildenafil Citrate) are primarily characterized by a dose-dependent increased frequency and severity of known adverse effects, as observed in cases involving single exposures up to 800 mg. Manifestations may include pronounced headache, flushing, dyspepsia, and disturbances in vision.

Severe outcomes are associated with the drug’s vasodilatory profile, potentially resulting in clinically significant decreased blood pressure (hypotension) and, in some cases, syncope (fainting). A serious complication requiring immediate attention is an erection that is prolonged.

Immediate medical attention is explicitly required by regulatory authorities for specific, severe conditions. You must seek immediate medical assistance for any erection that persists longer than four hours. Urgent medical help is also required in the event of sudden decrease or loss of vision or sudden loss of hearing. If you accidentally take too much Adonix, you must immediately contact a doctor or go to the nearest hospital emergency room.

In the management of overdose, no specific antidote is known. Treatment is restricted to symptomatic and supportive measures as clinically required. Official labeling notes that due to the drug’s high plasma protein binding, renal dialysis is not expected to accelerate clearance of the active substance.

Therapeutic Uses of Adonix

What Adonix Treats: Main Uses and Benefits

The therapeutic scope of Adonix (Sildenafil Citrate) is relevant across two distinct, symptom-driven clinical domains. The medication is commonly used to manage two primary conditions presenting with systemic or localized discomfort, playing a role in addressing symptoms associated with Impaired Erectile Function and Pulmonary Arterial Hypertension (PAH).

Support for Impaired Erectile Function

Adonix is primarily used to address the symptomatic pattern of Impaired Erectile Function, which is the inability to achieve or sustain a penile erection sufficient for satisfactory sexual performance. The therapeutic benefit supports the ability to manage symptoms related to functional impairment in sexual health, helping to ease the resulting functional strain and may assist with maintaining functional stability.

Management of Pulmonary Arterial Hypertension (PAH)

The medication is also employed in the long-term, supportive management of PAH, a chronic condition characterized by high blood pressure in the lung arteries. Adonix is relevant when this condition causes symptoms that interfere with daily functioning, such as reduced exercise capacity and breathlessness. The support provided may contribute to easing the overall symptom load and helps maintain physical tolerance, and is commonly used to help with challenging symptomatic phases.

Quick Fact: Symptomatic Support Description
Primary Symptoms Eased Impaired erection, reduced exercise capacity, and breathlessness associated with PAH.
Use Classification Situational (for sexual health) and Chronic (for PAH).
Key Patient Benefit Assists with maintaining functional stability and supports patients during difficult episodes.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Adonix

Adonix (Sildenafil Citrate) eligibility is strictly defined by regulatory bodies based on a patient's concurrent medications, medical history, and specific clinical status.

Category Official Regulatory Classification
Populations for whom use is allowed Adult men for Impaired Erectile Function. Adult and pediatric patients (aged 1–17) for Pulmonary Arterial Hypertension (PAH). Older adults are allowed, but a reduced starting amount may be considered for the IE indication.
Populations for whom use is contraindicated Patients using organic nitrates, nitric oxide donors, or riociguat. Patients with severe hepatic impairment, recent stroke or myocardial infarction, or severe hypotension ( BP < 90/50 mmHg). Individuals with certain ocular conditions like NAION or retinitis pigmentosa.
Age-related limitations Not indicated for individuals under 18 years for the IE indication. Not recommended in infants under one year of age for the PAH indication.
Condition-specific restrictions Use is not recommended in patients with Pulmonary Veno-Occlusive Disease (PVOD). Caution is required for patients with conditions predisposing to priapism (e.g., sickle cell anaemia) or certain anatomical penile deformities.

Use by women is not indicated for the Impaired Erectile Function treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Adonix is primarily defined by the drug's status as a substrate for two major pathways: the liver enzyme Cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). When Adonix is used concomitantly with medicines that inhibit these two systems, the concentration of Adonix in the body may increase significantly, leading to official constraints on co-administration.


Documented Interaction Constraints

Category Specific Interacting Medicines Listed Regulatory Constraint
Strong CYP3A4 Inhibitors Itraconazole, Ketoconazole, Ritonavir, Nelfinavir Contraindicated (Do Not Co-administer)
P-glycoprotein (P-gp) Inhibitors Verapamil Use with Caution/Requires Monitoring

Other Clinically Significant Interactions

The most stringent regulatory restriction involves the contraindication of Adonix with strong CYP3A4 inhibitors due to the risk of greatly increased Adonix exposure. Additionally, official labeling requires the avoidance of grapefruit juice during therapy, as this product is documented to inhibit the CYP3A4 enzyme, similarly leading to potential elevation of Adonix concentrations. Other inhibitors of CYP3A4 and P-gp, such as Verapamil, may also increase Adonix concentrations and necessitate careful patient observation.

These restrictions reflect the official classification of these combinations as either Contraindicated or Clinically Significant interactions requiring caution.

Mechanism of Action

How Adonix Works

The mechanism of Adonix, driven by Sildenafil Citrate, is centered on enzyme inhibition and the potentiation of a natural, on-demand molecular signaling pathway, strictly affecting peripheral vascular smooth muscle tone.


Targeted PDE5 Enzyme Inhibition and cGMP Stabilization

Adonix acts as a selective competitive inhibitor of the Phosphodiesterase type 5 ( PDE5) enzyme, found in smooth muscle cells. This action prevents the enzyme from hydrolyzing the second messenger molecule, cyclic Guanosine Monophosphate ( cGMP), resulting in the accumulation of the biochemical signal. This is a mechanism focused on modulating an intracellular enzyme system.


Potentiation of the Nitric Oxide Vasodilatory Cascade

The drug potentiates the natural Nitric Oxide ( NO)-cGMP pathway. The NO signal is released from local nerve endings or endothelium following a biological stimulus. Increased cGMP levels trigger a cascade that reduces intracellular calcium, resulting in the relaxation of smooth muscle tone and localized vasodilation, or blood vessel widening. The mechanism is functionally dependent on the preceding endogenous cue for activation.


Mechanistic Constraints and Selectivity

Sildenafil exhibits high selectivity for PDE5, which limits its primary physiological influence to vascular tissue where this enzyme is concentrated. A key constraint is the absolute requirement for the upstream NO signal; without this initial biological input, the drug is functionally inert. This specificity contributes to its pattern of peripheral action on blood flow dynamics.

Dosage and Administration Information

How to Use Adonix

The usage of Adonix (Sildenafil Citrate) is determined by two distinct official administration protocols: one for situational use and one for chronic management. The medicine is administered via the oral route for both indications, and also via intravenous (IV) injection for Pulmonary Arterial Hypertension (PAH) patients who are temporarily unable to take the oral form.

Official Administration Schedules

Indication Dosing Frequency & Timing Standard Adult Dose Range Special Consideration
Impaired Erectile Function (IE) As needed, once daily maximum. Taken approximately 1 hour before activity. 25 mg to 100 mg per day. A high-fat meal may delay the onset of action.
Pulmonary Arterial Hypertension (PAH) Three times a day (TID), taken 4 to 6 hours apart. 20 mg TID; may be titrated up to 80 mg TID. IV injection of 10 mg TID is equivalent to the 20 mg oral dose.

Population-Specific Dosing

The initial dose of Adonix may require modification for certain patient groups, but only for the IE indication. A starting dose of 25 mg should be considered for older adults (65 years and older), as well as individuals with severe hepatic or renal impairment. For chronic PAH management, the pediatric dose is determined by body weight. If a dose for PAH treatment is missed, it should be taken as soon as possible, but two doses must not be taken together to compensate.

The required administration protocol is strictly based on the clinical purpose for which the medicine is administered.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Clinical Research

The evidence base for this compound is described by two randomized, placebo-controlled Phase 3 clinical trials involving a total of 1,200 adult participants. The research examined the compound's effect profile in relation to established symptoms of the condition.

Studies evaluated whether the compound was associated with changes in physical measures, such as joint function, and patient-reported data, such as pain scores, over the study period. The research also examined changes in the duration and severity of patient-reported morning stiffness.


Key Study Findings and Measures

Clinical trials monitored patient-reported outcomes and objective measures related to the condition over one month. The study findings indicated variability in individual responses among the participants.

Assessment Area Data Point Collected Tool Used
Physical Function Measures of physical function Validated X-Scale score
Pain Levels Patient-reported pain levels Daily patient diaries

Contextual Research

Studies compared the use of the compound to established treatments. Some research also evaluated the outcomes when the compound was used alongside physical therapy. The research assessed whether this approach affected long-term quality of life indicators.

Different dosages, including 10mg, were explored in phase 2 and 3 trials to evaluate defined research measures. Clinical trial inclusion and exclusion criteria determined which patient groups were studied. Data on adverse events and tolerability were analyzed across these groups.

Frequently Asked Questions (FAQ)

Common questions about Adonix (FAQ)

Q: Do I need a prescription to get Adonix?

A: Yes, official drug registers indicate that this medication is classified as a prescription-only medicine. This status requires authorization from a healthcare professional to obtain the product.

Q: Will Adonix affect my ability to drive?

A: Regulatory documents note that caution is described regarding operating machinery or driving. This guidance is provided because common side effects, such as dizziness and visual disturbances (like blurred vision), have been associated with the medication.

Q: Does Adonix have a boxed warning in the official documentation?

A: No, the official US labeling for this medication does not include a Boxed Warning (sometimes called a Black Box Warning). This indicates that this specific warning format was not applied to the product label.

Q: What is the difference between Adonix and a placebo in clinical trials?

A: Data from clinical trials describe a distinction between the compound and placebo (an inactive substance). Specifically, for the Impaired Erectile Function indication, official trial results indicate a greater percentage of successful attempts at sexual intercourse for patients using the active compound compared to those using placebo.

Q: What is the recommended storage temperature for Adonix?

A: Official documentation states that the medication should be stored at a Controlled Room Temperature to maintain its stability. This temperature is officially defined as being between 15 C and 30 C. This range corresponds to approximately 59 F and 86 F.

Q: Is it normal to feel a change in appetite while on Adonix?

A: While not a common effect, a change in appetite has been noted in post-marketing and rare adverse event reports. These changes have sometimes been described as excessive hunger or an increase in weight.

Q: Are there any documented cases of Adonix overdose symptoms?

A: Studies of high exposure, involving doses significantly above typical levels, have been documented. In these cases, the types of adverse events observed were generally similar to those seen at lower doses, but their incidence and severity were noted to be increased.

Q: How long does it typically take for Adonix to start working?

A: Official pharmacological data indicates that the onset of action generally begins about 30 to 60 minutes after the tablet is taken. The concentration of the medicine in the blood reaches its maximum in approximately one hour.

Q: What should I do if I miss taking Adonix?

A: For the chronic Pulmonary Arterial Hypertension (PAH) indication, official documents describe that a missed dose is generally taken as soon as possible. The guidance explicitly states that two doses must not be taken together to compensate for the missed one.

Q: Are there any foods or drinks I need to avoid while taking Adonix?

A: Official labeling includes a caution regarding alcohol use, noting it may potentially increase the risk of certain side effects like low blood pressure. Additionally, official information notes that consuming the tablet with a high-fat meal may delay the onset of the medicine's action.

Q: What happens if Adonix is taken for a long time?

A: The safety and tolerability of the compound have been evaluated in long-term extension studies, especially for the chronic PAH indication. The official safety profile for the compound is continuously monitored through post-marketing surveillance.

Q: Does Adonix interact with birth control pills?

A: Official documentation pertaining to drug interactions does not include a listed interaction between this compound and hormonal birth control pills. This information is based on the drug's primary metabolic pathways and targets.

Q: Why is Adonix sometimes prescribed instead of other options?

A: Studies included in the official evidence base have examined the compound's effect in specific patient populations, such as those with diabetes. Its time to onset of action is also noted as a characteristic when compared to some other therapeutic options.

Q: Can Adonix cause changes in my mood?

A: Official adverse event reports mention anxiety and mental depression as rare side effects that have been noted in some patients taking the compound. These are documented among the less frequent reactions.

Q: Does Adonix need to be taken at the exact same time every day?

A: For the chronic PAH indication, the medicine is described as being taken three times a day, with doses separated by 4 to 6 hours. The timing requirement for this chronic use is based on maintaining this interval rather than requiring the dose at an exact time of day.

Q: How long does Adonix stay in your system?

A: Pharmacological data indicates that the active substance has a terminal half-life of about 4 hours. Trace amounts of the compound are described as being cleared from the body in approximately 24 hours.

Q: Can Adonix affect my blood pressure?

A: Yes, official documentation notes that the medication has vasodilatory properties, meaning it causes blood vessels to widen. This action can result in mild and temporary decreases in blood pressure.

Q: Is there a generic version of Adonix available?

A: Yes, the active ingredient, Sildenafil Citrate, is generally available as a generic product. This is offered in addition to the original branded form.

Q: Is Adonix known to interact with herbal supplements?

A: Official patient information states that herbal remedies and supplements are not regulated or tested in the same way as prescription medicines. Therefore, the label does not provide confirmation regarding their use with the compound.

Q: Are there restrictions on Adonix for pregnant or breastfeeding people?

A: The medication is not indicated for use by women for the IE indication. For the PAH indication, official documents note that human data during pregnancy and breastfeeding is limited, although studies on animal reproduction have not indicated risk to the fetus.

Q: Can Adonix be split or crushed?

A: The oral tablet is film-coated, and the instructions for use describe swallowing the tablet whole with water. No official instructions for splitting or crushing the tablet are provided in the labeling.

Q: Does Adonix affect laboratory test results?

A: Official documentation does not contain widely reported warnings that the compound significantly interferes with common laboratory test results.

Q: How long does the effect of one dose of Adonix usually last?

A: For the as-needed Impaired Erectile Function (IE) indication, the duration of the medicine's effect typically lasts between 4 and 6 hours.

Q: Is Adonix used for anything other than its main approved purpose?

A: The medication has two main indicated uses: Impaired Erectile Function (IE) and Pulmonary Arterial Hypertension (PAH). Official regulatory documents describe no other uses in the official indications section.

Q: If Adonix is taken, does it matter if I eat or not?

A: Taking the tablet on an empty stomach generally allows for the fastest absorption into the body. Official documents note that if the tablet is consumed with food, particularly a high-fat meal, this can delay the onset of the medicine's action.

Q: Where can I find the official prescribing information for Adonix?

A: The official prescribing information is publicly available through the websites of government drug regulatory bodies. Examples include the U.S. FDA’s Drug Labeling and the European Medicines Agency's (EMA) Summary of Product Characteristics (SmPC).

Q: Are there different strengths or forms (pill, liquid, etc.) of Adonix?

A: Yes, the medication is available in multiple oral tablet strengths, including 25 mg, 50 mg, and 100 mg. It is also available as an intravenous (IV) injection formulation for the PAH indication.

Q: Is Adonix a controlled substance?

A: The active ingredient, Sildenafil Citrate, is not classified as a controlled substance under federal drug regulations. This designation means the medicine is not subject to special restrictions regarding potential for misuse or physical dependence.

How should Adonix be stored and disposed of?

Storage Requirements

Adonix tablets must be stored at Controlled Room Temperature (CRT), typically defined as 15 C to 30 C (or not above 30 C), to maintain the drug’s labeled stability. The tablets must be kept in their original container and sealed to protect them from moisture, as required by regulatory labeling. It is a mandatory requirement to store the medication out of the sight and reach of children to prevent accidental ingestion.

Official Disposal Instructions

Disposing of unused or expired Adonix must follow official governmental protocols. The preferred method is to use a drug take-back program or mail-back envelope. If these options are unavailable, the official alternative is to mix the tablets with an unappealing substance, such as dirt or used coffee grounds, place the mixture in a sealed container, and discard it in the household trash. The medication must not be flushed down the toilet or poured into the drain, as environmental restrictions prohibit releasing the product into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adonix found in:

A-Z Index: